This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
by Kinjel Shah
Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.
Company News for Apr 24, 2024
by Zacks Equity Research
Companies in The News Are: UPS,PM,NVS,IVZ
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
Compared to Estimates, Novartis (NVS) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Novartis (NVS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
by Zacks Equity Research
Novartis (NVS) comfortably beats first-quarter earnings and sales estimates. The company ups its outlook for 2024 on strong growth across key brands.
The Zacks Analyst Blog Highlights Novartis, American Express, ConocoPhillips, Netflix and Schlumberger
by Zacks Equity Research
Novartis, American Express, ConocoPhillips, Netflix and Schlumberger are part of the Zacks top Analyst Blog.
Top Analyst Reports for Novartis, American Express & ConocoPhillips
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), American Express Company (AXP) and ConocoPhillips (COP).
Novartis (NVS) to Report Q1 Earnings: What to Expect?
by Ekta Bagri
Novartis (NVS) key drugs Entresto, Kisqali and Pluvicto are likely to have fueled its top and bottom-line numbers in the first quarter.
Exploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Evaluate the expected performance of Novartis (NVS) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
by Zacks Equity Research
Novartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for the treatment of immunoglobulin A nephropathy, a heterogeneous, progressive, rare kidney disease.
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
by Zacks Equity Research
Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
Novartis (NVS) to Undertake Job Cuts in Development Department
by Zacks Equity Research
Novartis (NVS) is set to cut jobs by 680 in its development organization to reshape workforce.
Novartis (NVS) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
In the latest trading session, Novartis (NVS) closed at $95.79, marking a -1.14% move from the previous day.
Novartis (NVS) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
In the most recent trading session, Novartis (NVS) closed at $94.41, indicating a -1.52% shift from the previous trading day.
Investors Heavily Search Novartis AG (NVS): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Novartis (NVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novartis (NVS) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
Novartis (NVS) closed at $95.88 in the latest trading session, marking a +0.64% move from the prior day.
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
by Zacks Equity Research
Mesoblast (MESO) gains as the FDA states that the available phase III data for lead candidate, remestemcel-L, is sufficient to support a regulatory filing for pediatric SR-aGVHD indication.
Novartis (NVS) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
In the most recent trading session, Novartis (NVS) closed at $95.73, indicating a -0.52% shift from the previous trading day.
Novartis (NVS) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
In the most recent trading session, Novartis (NVS) closed at $96.32, indicating a +0.42% shift from the previous trading day.
Novartis (NVS) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the latest trading session, Novartis (NVS) closed at $95.92, marking a -1.39% move from the previous day.
Here is What to Know Beyond Why Novartis AG (NVS) is a Trending Stock
by Zacks Equity Research
Novartis (NVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Novartis (NVS) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the most recent trading session, Novartis (NVS) closed at $99.77, indicating a -1.58% shift from the previous trading day.